Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 8/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | HAT1 | O14929 | 3/20 | 0.35 |
| ▸ | EP300 | Q09472 | 3/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22077994 | 0.86 | ADH5 (0.38) | ADH5DHODHCNR2HAT1EP300 | |
| SCHEMBL22078073 | 0.85 | ADH5 (0.44) | ADH5TBXAS1CYP4Z1 | |
| SCHEMBL30772941 | 0.83 | ADH5 (0.41) | ADH5DHODHCNR2TBXAS1STING1 | |
| SCHEMBL20536624 | 0.83 | ADH5 (0.41) | ADH5DHODHCNR2TBXAS1STING1 | |
| SCHEMBL22078074 | 0.80 | TBXAS1 (0.47) | ADH5CNR2HAT1EP300TBXAS1 | |
| SCHEMBL22078071 | 0.80 | PSEN1 (0.48) | TBXAS1 | |
| SCHEMBL22077254 | 0.80 | ESR1 (0.41) | CNR2TBXAS1 | |
| SCHEMBL22078065 | 0.79 | ADH5 (0.44) | ADH5DHODHTBXAS1CYP4Z1 | |
| SCHEMBL22078080 | 0.79 | ADH5 (0.46) | ADH5DHODHCNR2TBXAS1STING1 | |
| SCHEMBL22077044 | 0.78 | TBXAS1 (0.47) | ADH5HAT1EP300TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609867-B1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSNO THERAPEUTICS INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSNO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSNO THERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSNO THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655244-B2 | Carbazole compounds and methods of use thereof | GSR, CBR3, CBR1 | ADH5 93/4885DHODH 302/4885CNR2 291/4885 |
| US-20200181129-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GSR, CBR3, CBR1 | ADH5 93/4885DHODH 302/4885CNR2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.